Buy CVS Stock Ahead of Its Upcoming Earnings?
CVS Health (NYSE:CVS) is scheduled to announce its earnings on Thursday, July 31, 2025. For event-driven traders, analyzing the stock's historical behavior around earnings releases can provide valuable context.
Over the past five years, CVS stock has shown a slight tendency toward positive one-day returns post-earnings. In 55% of instances, the stock saw a positive return, with a median gain of 4.4% and a maximum one-day increase of 14.9%.
While the actual results relative to analyst consensus and market expectations will be the primary driver of the stock's immediate reaction, understanding these historical patterns can potentially improve trading odds. Traders typically employ two main strategies when approaching earnings events:
The consensus estimate for CVS's upcoming earnings report is $1.46 per share on revenue of $94.59 billion. This projected earnings per share is lower than the $1.83 per share reported in the same quarter last year, despite an increase in revenue from $91.23 billion. This expected decline in profitability is partly attributed to rising medical costs impacting overall margins.
From a fundamental perspective, CVS Health currently holds a market capitalization of $76 billion. Over the last twelve months, the company generated substantial revenue of $379 billion, achieving operational profitability with $11 billion in operating profits and a net income of $5.3 billion.
That said, if you seek upside with lower volatility than individual stocks, the Trefis High Quality portfolio presents an alternative – having outperformed the S&P 500 and generated returns exceeding 91% since its inception. Also, see – Buy Or Sell SOFI Stock At $24?See earnings reaction history of all stocks
CVS Stock Historical Odds of Positive Post-Earnings Return
Some observations on one-day (1D) post-earnings returns:
Additional data for observed 5-Day (5D), and 21-Day (21D) returns post earnings are summarized along with the statistics in the table below.
CVS 1D, 5D, and 21D Post Earnings Return
CVS Stock Correlation Between 1D, 5D, and 21D Historical Returns
A relatively less risky strategy (though not useful if the correlation is low) is to understand the correlation between short-term and medium-term returns post earnings, find a pair that has the highest correlation, and execute the appropriate trade. For example, if 1D and 5D show the highest correlation, a trader can position themselves "long" for the next 5 days if 1D post-earnings return is positive. Here is some correlation data based on 5-year and 3-year (more recent) history. Note that the correlation 1D_5D refers to the correlation between 1D post-earnings returns and subsequent 5D returns.
CVS Correlation Between 1D, 5D and 21D Historical Returns
Learn more about Trefis RV strategy that has outperformed its all-cap stocks benchmark (combination of all 3, the S&P 500, S&P mid-cap, and Russell 2000), to produce strong returns for investors. Separately, if you want upside with a smoother ride than an individual stock like CVS Health, consider the High Quality portfolio, which has outperformed the S&P, and clocked >91% returns since inception.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 minutes ago
- Yahoo
MetLife (MET) To Report Earnings Tomorrow: Here Is What To Expect
Global insurance giant MetLife (NYSE:MET) will be reporting results this Wednesday afternoon. Here's what investors should know. MetLife beat analysts' revenue expectations by 3% last quarter, reporting revenues of $18.83 billion, up 10.6% year on year. It was a slower quarter for the company, with a significant miss of analysts' book value per share estimates and a miss of analysts' EPS estimates. Is MetLife a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting MetLife's revenue to be flat year on year at $18.64 billion, in line with its flat revenue from the same quarter last year. Adjusted earnings are expected to come in at $2.16 per share. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. MetLife has missed Wall Street's revenue estimates four times over the last two years. Looking at MetLife's peers in the life insurance segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Corebridge Financial delivered year-on-year revenue growth of 5.8%, beating analysts' expectations by 7.3%, and Lincoln Financial Group reported revenues up 4.4%, topping estimates by 1.1%. Lincoln Financial Group traded up 7.8% following the results. Read our full analysis of Corebridge Financial's results here and Lincoln Financial Group's results here. Debates around the economy's health and the impact of potential tariffs and corporate tax cuts have caused much uncertainty in 2025. While some of the life insurance stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 2.9% on average over the last month. MetLife is down 5.3% during the same time and is heading into earnings with an average analyst price target of $94.14 (compared to the current share price of $75). Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
Yahoo
2 minutes ago
- Yahoo
HubSpot (HUBS) Reports Q2: Everything You Need To Know Ahead Of Earnings
Sales and marketing software maker HubSpot (NYSE:HUBS) will be announcing earnings results this Wednesday afternoon. Here's what to look for. HubSpot beat analysts' revenue expectations by 2% last quarter, reporting revenues of $714.1 million, up 15.7% year on year. It was a strong quarter for the company, with an impressive beat of analysts' billings estimates and a solid beat of analysts' EBITDA estimates. It added 10,319 customers to reach a total of 258,258. Is HubSpot a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting HubSpot's revenue to grow 16% year on year to $739.3 million, slowing from the 20.4% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $2.12 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. HubSpot has only missed Wall Street's revenue estimates once over the last two years, exceeding top-line expectations by 3.1% on average. Looking at HubSpot's peers in the sales and marketing software segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Freshworks delivered year-on-year revenue growth of 17.5%, beating analysts' expectations by 2.9%, and BigCommerce reported revenues up 3.2%, topping estimates by 1.3%. Freshworks traded down 2.5% following the results while BigCommerce was up 4.6%. Read our full analysis of Freshworks's results here and BigCommerce's results here. The euphoria surrounding Trump's November win lit a fire under major indices, but potential tariffs have caused the market to do a 180 in 2025. While some of the sales and marketing software stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3% on average over the last month. HubSpot is down 7.8% during the same time and is heading into earnings with an average analyst price target of $736.74 (compared to the current share price of $512.20). When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we've found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 minutes ago
- Yahoo
Primerica Earnings: What To Look For From PRI
Financial services company Primerica (NYSE:PRI) will be reporting results this Wednesday after market hours. Here's what to expect. Primerica beat analysts' revenue expectations by 2.1% last quarter, reporting revenues of $803.6 million, up 9.4% year on year. It was a mixed quarter for the company, with net premiums earned in line with analysts' estimates but a slight miss of analysts' book value per share estimates. Is Primerica a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Primerica's revenue to grow 6.1% year on year to $786.1 million, slowing from the 9.8% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $5.20 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Primerica has missed Wall Street's revenue estimates four times over the last two years. Looking at Primerica's peers in the life insurance segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Corebridge Financial delivered year-on-year revenue growth of 5.8%, beating analysts' expectations by 7.3%, and Lincoln Financial Group reported revenues up 4.4%, topping estimates by 1.1%. Lincoln Financial Group traded up 7.8% following the results. Read our full analysis of Corebridge Financial's results here and Lincoln Financial Group's results here. The outlook for 2025 remains clouded by potential trade policy changes and corporate tax discussions, which could impact business confidence and growth. While some of the life insurance stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 2.9% on average over the last month. Primerica is down 2.8% during the same time and is heading into earnings with an average analyst price target of $307.29 (compared to the current share price of $265.39). Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
